Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Day One Biopharmaceuticals Inc
NASDAQ DAWN
Data sourced from
and
and
Download Data
Day One Biopharmaceuticals Inc Price to Book Ratio (P/B) on June 03, 2024: 3.88
Day One Biopharmaceuticals Inc Price to Book Ratio (P/B) is 3.88 on June 03, 2024, a 220.61% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
-
Day One Biopharmaceuticals Inc 52-week high Price to Book Ratio (P/B) is 2,269.78 on August 04, 2023, which is 58,389.64% above the current Price to Book Ratio (P/B).
-
Day One Biopharmaceuticals Inc 52-week low Price to Book Ratio (P/B) is -3.41 on February 06, 2024, which is -187.87% below the current Price to Book Ratio (P/B).
-
Day One Biopharmaceuticals Inc average Price to Book Ratio (P/B) for the last 52 weeks is 18.30.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DAWN
| CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
| IPO Date | May 27, 2021 |
| Location | United States |
| Headquarters | 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 174 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Key trends
Similar companies
Acumen Pharmaceuticals Inc
NA
NA
Eledon Pharmaceuticals Inc
NA
NA
StockViz Staff
September 16, 2024
Any question? Send us an email